Compare Carlyle Group Inc (CG) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carlyle Group Inc vs Twist Bioscience Corp — how do they compare? Carlyle Group Inc trades at $48.27 (market cap $17.23B), while Twist Bioscience Corp trades at $124 (market cap $7.72B). The key difference: Carlyle Group Inc is far larger — about 2.2× Twist Bioscience Corp's market cap, and Carlyle Group Inc pays a 2.9% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| CG | TWST | |
|---|---|---|
Market Cap | $17.23B | $7.72B |
Sector | Financials | Health |
52-Week High | $69.35 | $124.88 |
52-Week Low | $40.52 | $24.16 |
Dividend Yield | 2.9% | — |
Enterprise Value | — | $7.65B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
